Management of Osteoporosis

Publication Date: September 24, 2019

Key Points

Key Points

Patients with non-metastatic cancer may be at risk for osteoporotic fractures due to baseline risks or due to the added risks associated with their cancer therapy.

Clinicians are advised to assess fracture risk using established tools.
  • For those with substantial risk of osteoporotic fracture the clinician should obtain a bone mineral density.

The bone health of all patients may benefit from optimizing nutrition, exercise and lifestyle.

When a pharmacologic agent is indicated, bisphosphonates or denosumab, at osteoporosis-indicated dosages, are the preferred interventions.

Assessment

...Assessme...

...Ris...

...ion 1.1. It is recommended that patients with n...

...dation 1.2. Clinicians should be aware that...

...ion 1.3. Clinicians may use a risk assessment t...


...Screening...

...tion 2.1. Patients with non-metastatic...

...dation 2.2. Patients with non-metastatic...


Treatment

...Treatme...

...3.1. Clinicians should encourage p...

...tion 3.2. Clinicians should activel...

...ation 3.3. Clinicians should activ...


...Pharmacological Inter...

...commendation 3.4. For patients with non-metasta...

...3.5. Provided T-score and/or risk assessment (e....


...gure 1. Algorithm for Maintaining Bone Healt...


...e 1. Osteoporotic Fracture Risk FactorsHaving...


...oss Associated with Various Cancer...


...mmonly used Bone Modifying Agents for the Pre...


...timated Drug Costs for Bone Modifying AgentsaHavin...